The adequacy of phosphorus binder prescriptions among american hemodialysis patients

Renal Failure

Volumn 34, Issue 10, 2012, Pages 1258-1263

  Huml, Anne M ^a,b   Sullivan, Catherine M ^a   Leon, Janeen B ^a   Sehgal, Ashwini R ^a,c  

^a Center for Reducing Health Disparities   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Adequacy; Binders; Hemodialysis; Phosphorus; Prescriptions

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; CARBONIC ACID; LANTHANUM; MAGNESIUM CARBONATE; PHOSPHORUS; SEVELAMER; SEVELAMER CARBONATE;

ADULT; ARTICLE; BINDING AFFINITY; DIET RESTRICTION; DIETARY INTAKE; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ACETATES; AGED; CALCIUM COMPOUNDS; CHELATING AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS; UNITED STATES;

EID: 84867738792     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.718724     Document Type: Article

References (45)

1. KDOQI. NKF KDOQI guidelines. Available at: Http://www. kidney.org/professionals/kdoqi/guidelines-bone/index.htm. Accessed July 2011.
2. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-"592.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):607- "617.
4. Ganesh SK, Stack AG, LevinNW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca PO(4) product, and parathyroid hormone with cardiacmortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131-"2138. (Pubitemid 32880350)
5. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771-"780. (Pubitemid 44215354)
6. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, RodriguezM, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46(1):68-"77. (Pubitemid 40848434)
7. Tentori F, Blayney M, Albert J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52(3):519-"530.
8. Wald R, Sarnak M, Tighiouart H, et al. Disordered mineral metabolism in hemodialysis patients: Analysis of cumulative effects in the hemodialysis (HEMO) study. Am J Kidney Dis. 2008;52(3):531-"540.
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8): 2208-"2218. (Pubitemid 39031360)
10. Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in hemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant. 1998;13(8):2037-"2040. (Pubitemid 28356772)
11. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial. 2004;17(3):209-"216. (Pubitemid 38824502)
12. Malluche HH, Mawad H. Management of hyperphosphatemia of chronic kidney disease: Lessons from the past and future directions. Nephrol Dial Transplant. 2002;17(7):1170-"1175. (Pubitemid 34812059)
13. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2004;44(S2):S34-"S38. (Pubitemid 39369939)
14. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. J Am Med Assoc. 2009;301 (6):629-"635.
15. Ashurst I, Dip PG, Dobbie H. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. J Ren Nutr. 2003;13(4):267-"274. (Pubitemid 38367740)
16. Mayne TJ, Benner D, Ricketts K, et al. Results of a pilot program to improve phosphorus outcomes in hemodialysis patients. [Published online ahead of print 2 November 2011]. J Ren Nutr. doi:10.1053/j.jrn.2011.08.006.
17. Morey B, Walker R, Davenport A. More dietetic time, better outcome? Nephron Clin Pract. 2008;109:c173-"c180.
18. Data.Medicare.Gov. Dialysis facility compare-listing by facility. Available at: Https://data.medicare.gov/dataset/Dialysis-Facility-Compare- Listing-by-Facility/23ew-n7w9. Accessed July 2011.
19. Daugirdas JT, Finn WF, Emmett M, Chertow GM. The frequent hemodialysis network trial group. The phosphate binder equivalent dose. Semin Dial. 2011;24(1):41-"49.
20. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: Does it matter in nephrology? Semin Dial. 2003;16(3):186- "188. (Pubitemid 37363217)
21. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial. 2007;20(4):295-"301.
22. Ramirez JA, Emmett M, White MG, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30:753-"759. (Pubitemid 17049596)
23. Finn WF. Phosphorus management in end-stage renal disease. Semin Dial. 2005;18(1):8-"12. (Pubitemid 40348269)
24. Kooienga L. Phosphorus balance with daily dialysis. Semin Dial. 2007;20(4):342-"345.
25. Browner WS, Newman TB, Hulley SB. Estimating sample size and power: Applications and examples. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB, eds. Designing Clinical Research. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2007:65-"94.
26. Kalantar-Zadeh K, Ikizler A, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis. 2003;42 (5):864-"881. (Pubitemid 37322905)
27. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-"1096.
28. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: A randomized trial. Clin J Am Soc Nephrol. 2009;4(1):178-"185.
29. Finn W, Kingma-Johnson I. Urinary phosphorus excretion is a valuable measure of total body phosphorus burden in patients with CKD stages 3 and 4. J Am Soc Nephrol. 2008;19: 320A-321A.
30. Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium-And aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12:1640-"1644. (Pubitemid 27346290)
31. Sullivan CM, Leon JB, Sehgal AS. Phosphorus-containing food additives and the accuracy of nutrient databases: Implications for renal patients. J Ren Nutr. 2007;17(5):350-"354. (Pubitemid 47284907)
32. Sarathy S, Sullivan C, Leon JB, Sehgal AR. Fast food, phosphorus containing food additives, and the renal diet. J Ren Nutr. 2008;18(5):466- "470.
33. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: Implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4(8): 1370-"1373.
34. Calvo MS. Dietary considerations to prevent loss of bone and renal function. Nutrition. 2000;16(7-"8):564-"566. (Pubitemid 30445110)
35. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:519-"530.
36. PhosLo. Waltham, MA: Fresenius Medical Care; 2007.
37. Renagel. Cambridge, MA: Genzyme Corporation; 2007.
38. Renvela. Cambridge, MA: Genzyme Corporation; 2010.
39. Fosrenol. Wayne, PA: Shire US Inc.; 2011.
40. Murray L (ed.). Dosing information for dyspepsia products. In: PDR for Nonprescription Drugs, Dietary Supplements, and Herbs. Montvale, NJ: Thomson PDR; 2005:160.
41. Benini O, D'Alessandro C, Gianfaldoni D, Cupisti A. Extraphosphate load from food additives in commonly eaten foods: A real and insidious danger for renal patients. J Ren Nutr. 2011;21 (4):303-"308.
42. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory hemodialysis patients: Comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19:1842- "1848. (Pubitemid 38961397)
43. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2.
44. Schorr M, Manns BJ, Culleton B, et al. The effect of nocturnal and conventional hemodialysis on markers of nutritional status: Results from a randomized trial. J Ren Nutr. 2011;21(3):271-" 276.
45. Kjellstrand CM, Ing TS, Kjellstrand PT, Odar-Cederlof I, Lagg CR. Phosphorus dynamics during hemodialysis. Hemodial Int. 2011;15(2):226-"233.